Related Experiment Video

Updated: May 5, 2026

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

8.0K

Tumor Heterogeneity and the Immune Response in Non-Small Cell Lung Cancer: Emerging Insights and Implications for

Michael S Oh1, Jensen Abascal1, Austin K Rennels1

  • 1Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.

Cancers
|March 28, 2025
PubMed

Insights

Tumor heterogeneity in non-small cell lung cancer (NSCLC) drives resistance to immune checkpoint inhibitors (ICIs). Understanding clonal evolution and diverse factors is key to overcoming treatment challenges.

Area of Science:

  • Oncology
  • Immunology
  • Genomics

Background:

  • Immune checkpoint inhibitors (ICIs) show limited efficacy in non-small cell lung cancer (NSCLC) due to treatment resistance.
  • Tumor heterogeneity, encompassing neoantigen diversity and clonal evolution, is a critical factor in cancer treatment resistance.

Purpose of the Study:

  • To review the role of tumor heterogeneity in immune surveillance and ICI resistance in NSCLC.
  • To explore the spatial and temporal evolution of tumor heterogeneity using modern technologies.
  • To discuss implications of heterogeneity on immunotherapy and strategies to overcome resistance.

Main Methods:

  • Review of current literature on tumor heterogeneity, neoantigens, and ICI resistance in NSCLC.
  • Analysis of genomic, epigenetic, and metabolic factors contributing to heterogeneity.
  • Examination of spatial and temporal evolution of tumor clones.

Main Results:

  • Tumor heterogeneity significantly impacts immune surveillance and response to ICIs in NSCLC.
  • Neoantigen diversity and clonal selection influence immunotherapy efficacy.
  • Epigenetic and metabolic factors contribute to immune evasion and resistance.

Conclusions:

  • Addressing tumor heterogeneity is crucial for improving ICI efficacy in NSCLC.
  • Strategies targeting diverse sources of heterogeneity may overcome therapeutic resistance.
  • Further research into clonal evolution and its impact on the tumor immune microenvironment is warranted.
Keywords:
heterogeneityimmunotherapynon-small cell lung cancertumor evolution

More Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.2K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.8K

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K